Holding in Company

RNS Number : 6073J

ReNeuron Group plc

01 April 2010

 



ReNeuron Group PLC ("the Company")

 

Shareholding

Guildford, UK, 1 April 2010: ReNeuron Group plc (LSE: RENE.L) has received notification that Mr. Charles Good now holds 32,575,000 ordinary shares in the Company, representing 7.442% of the Company's outstanding share capital.

-Ends-

Enquiries:

Michael Hunt, Chief Executive Officer Dr John Sinden, Chief Scientific Officer ReNeuron Group plc	[phone]
Jonathan Birt, Susan Quigley Financial Dynamics	[phone]
Simon Leathers, Emma Earl Daniel Stewart & Company plc	[phone]
Alastair Stratton, Steve Quinn Matrix Corporate Capital LLP	[phone]

About ReNeuron

ReNeuron is a leading, UK-based stem cell business.  Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has regulatory approval for a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients.  Patient recruitment for this trial is expected to commence shortly. The Company is also developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com

 

END

 

 

HOLGIGDSLSGBGGB